Personal Finance
ACADIA Cares ™ is our way of showing how we support the community of patients that we serve with innovative therapies today and beyond. Scientific Publications. The Lancet, 383, 533-540 (2014). This indication presents a Management took proactive steps to adapt to the dynamic environment created by the COVID-19 pandemic. The $90.1 million in revenue came from 32% volume growth year over year. See you at the top!
"The company remains on track to deliver a second indication of Nuplazid for treatment of dementia-related psychosis (DRP).
With the recent collaboration, potential catalysts, and expansion of leadership, Acadia's stock looks ready to run higher. With a strong performance in the first quarter, Acadia seems positioned to handle any challenges that may arise in the rest of the year. Here's what investors need to know.ACAD earnings call for the period ending March 31, 2020.ACAD earnings call for the period ending December 31, 2019.ACAD earnings call for the period ending September 30, 2019.ACAD earnings call for the period ending June 30, 2019.ACAD earnings call for the period ending March 31, 2019.ACAD earnings call for the period ending December 31, 2018.The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
This newly created position will allow Acadia to source and create new business opportunities to expand on its innovative pipeline.Schneyer comes to the job as a former vice president of business development at Pfizer's Upjohn division, and his nine-plus years of experience -- overseeing strategic transactions including licensing agreements, product acquisitions and divestitures, collaborations, and company acquisitions -- will be quite valuable to Acadia over the long term.
The stock has a 52-week-high of $58.72 and a 52-week-low of $23.77. Retirement
This could drive the stock price higher, and it would create new avenues for top-line growth. About Us As mentioned, Acadia quickly adopted a virtual presence, incorporating a portal that provides healthcare providers with promotional and educational material, supporting the shift into telemedicine, and engaging with patients via online tools.The company is supporting its patients by continuing to deliver Nuplazid directly to patients' homes or through long-term care pharmacies and facilities, providing an uninterrupted supply of medicine even during challenging times created by COVID-19.
On May 7, Acadia announced that it had entered into a licensing agreement and research collaboration with Vanderbilt University. Its current ratio -- a measure of liquidity -- is 7.2, meaning it has a lot of short-term asset value respective to the value of its short-term liabilities. This collaboration provides Acadia with a portfolio of early-stage clinical candidates that will complement the current pipeline of CNS therapies and help build its long-term growth strategy.
Along with strategy, Acadia continues to improve its management team. Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. This value is in line with the broader biotechnology industry's average of 6.8. ACADIA Pharmaceuticals earned $0.27 in the second quarter, compared to $0.38 in the year-ago quarter. That still represents 28% sales growth year over year. Company Information. Annual Report Corporate Presentation. The gross-to-net adjustment -- which accounts for pricing changes such as discounts and rebates -- was 25.4% for Q1 2020. To share our passion for improving the lives of patients with central nervous (CNS) disorders and the people that care for them, our employees seek opportunities to contribute and participate in various patient focused causes and events. Retirement Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing. Let's conquer your financial goals together...faster. Investing Basics Acadia Pharmaceuticals's first-quarter sales were driven by strong execution in marketing and commercial strategy. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life.
Personal Finance